Navigation Links
Research spinoff ReXceptor gets license for Alzheimer's treatment

CLEVELAND Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

Gary Landreth, PhD, the Riuko and Archie G. Co Professor of Neurosciences, and his then-graduate student, Paige Cramer, PhD, co-founded ReXceptor after discovering that bexarotene (a medication trademarked as Targretin) reversed AD symptoms in mice within 72 hours of a single dose of treatment. Published last year in the journal Science, their results drew international interest, including stories in the Wall Street Journal and on CNN.

The U.S. Food and Drug Administration originally approved bexarotene for the treatment of cutaneous T-cell lymphomasa form of skin cancerin 1999. But Landreth, director of the medical school's Alzheimer's Research Laboratory, Cramer and their colleagues found that the medication significantly clears amyloid beta, a protein implicated in the development of Alzheimer's disease when it accumulates in the brain.

The researchers demonstrated that a dose of bexarotene (a retinoid X receptor (RXR) agonist) clears amyloid beta build-up by 25 percent within six hours, an effect that lasted for up to three days. Cognitively impaired mice resumed normal behaviors (demonstrating a restored sense of smell and instinctive interest in nest-building) within 72 hours of receiving the drug.

More than 5.4 million Americans suffer from Alzheimer's disease today, and that figure is expected to more than triple by the year 2050. Translating Case Western Reserve's groundbreaking research into a treatment available for patients is a complex process, but the researchers have great hope for the promise of their approach.

The first stage of testing will involve healthy volunteers, explained Michael Haag, the university's interim director of technology management and the chief executive officer for ReXceptor. Essentially, the researchers hope to prove that the medication acts on amyloid beta in the human brain in a manner similar to the one observed in animal studies. In lay terms, bexarotene functions as a kind of chaperone that escorts the problematic protein out of the cerebral area.

"This is an important proof-of-mechanism study that is a prerequisite for subsequent clinical evaluation of this drug in Alzheimer's patients," Landreth explained.

To date ReXceptor has secured $1.4 million to advance its work. This support includes a landmark collaboration between the Alzheimer's Drug Discovery Foundation and the BrightFocus Foundation to fund early-stage research. The arrangement includes The Charles Evans Foundation/Alzheimer's Drug Discovery Award to ReXceptor of $500,000 and a $250,000 contribution from BrightFocus to the collaboration with ADDF. The company also received two anonymous investments totaling $450,000, and $200,000 from Case Western Reserve.

This new funding has allowed ReXceptor to enter into a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial. C2N Diagnostics will provide its proprietary stable isotope labeling (SILK) platform to measure the metabolism of both brain-derived amyloid beta and apolipoprotein E in the human clinical study.

Haag credited the university's Office of Research and Technology Management, along with the medical school's chief translational officers and Council to Advance Human Health, with providing critical guidance and support in bringing the company to this stage.


Contact: Marv Kropko
Case Western Reserve University

Related biology news :

1. New research projects to enhance bioinformatics and computational biology tools and methodologies
2. Researchers pinpoint how trees play role in smog production
3. CNIO researchers capture the replication of the human genome for the first time
4. Cleveland Clinic research shows gut bacteria byproduct predicts heart attack and stroke
5. Scientists awarded $5.5 million for wheat, rice blast research
6. New research points to benefits of eggs, even for those at cardiovascular risk
7. New research examines connection between inflammatory stimulus and Parkinsons disease
8. Penn State Hass avocado research poster wins American Society For Nutrition Annual Awards
9. Large animal models of Huntingtons disease offer new and promising research options
10. New research constructs ant family tree
11. Researchers abuzz over caffeine as cancer-cell killer
Post Your Comments:
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... SHPG ) announced today that Jeff ... 27 th Annual Healthcare Conference in New York ... a.m. EST (1:30 p.m. GMT). --> SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
(Date:11/24/2015)... 2015  Twist Bioscience, a company focused on ... Twist Bioscience chief executive officer, will present at ... 1, 2015 at 3:10 p.m. Eastern Time at The Lotte ... --> --> About ... is on Twitter. Sign up to follow our ...
Breaking Biology Technology: